Sun Yat-sen University: all 1,681 studies

Page 9 of 17. Open to participants first (610), then studies with results posted, then the rest; newest registration first within each.

• G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05222009Phase 1
• Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
• TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3
• A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Phase 2
• Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Phase 3
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
• Visual Function in Pediatric Patients With Posterior Lens OpacitiesCompletedNCT05207007
• Intelligent Cataract Screening With Portable Slit-lampStatus unknownNCT05204095
• Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal CarcinomaActive, not recruitingNCT05201859Phase 2
• Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized TrialActive, not recruitingNCT05198609Phase 3
• Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05193617Phase 2
• Trabeculectomy Versus Peripheral Iridectomy Plus Goniotomy in Advanced PACGStatus unknownNCT05163951Not applicable
• MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal TumorStatus unknownNCT05163509Phase 2
• Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05162872Phase 2
• Accuracy Evaluation of Artificial Intelligence Assisted Liver Tumor Ablation Path PlanningStatus unknownNCT05161624
• PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT05156554Not applicable
• Olfactory Change After Chemo-radiotherapy for Nasopharyngeal CarcinomaStatus unknownNCT05146050
• The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective StudyCompletedNCT05121571Not applicable
• Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)Status unknownNCT05115409Phase 2
• Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast CancerCompletedNCT05114720Phase 3
• Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal SinusesStatus unknownNCT05114707Phase 2
• Change of Circulating Tumor Cells During Laparoscopic or Transanal Endoscopic Surgery for Rectal Cancer.Active, not recruitingNCT05109130
• Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Phase 2
• Mutation Detection for VRLStatus unknownNCT05102994
• Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCLStatus unknownNCT05093140Phase 2
• Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 VaccinationStatus unknownNCT05087173Not applicable
• Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIITStatus unknownNCT05084079Phase 4
• Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty LiverStatus unknownNCT05076058Not applicable
• Milk Supplementation and Bone Health in ChildrenStatus unknownNCT05074836Not applicable
• PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA PatientsCompletedNCT05060471Phase 2
• Reconstruction Technology to Auxiliary Diagnosis and Guarantee Patient PrivacyStatus unknownNCT05058599
• Verification of Harmonization of Plasma Epstein-Barr Virus DNA MeasurementsStatus unknownNCT05037357
• Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.CompletedNCT05027386Phase 1/2
• Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated RadiotherapyCompletedNCT05020067Phase 2
• Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerStatus unknownNCT05016544Phase 1/2
• Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT05010434Phase 2
• Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Phase 2
• Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05008471Not applicable
• Effect of Probiotics on Cardiometabolic HealthCompletedNCT05005754Not applicable
• Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCStatus unknownNCT05004831Phase 2
• Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerStatus unknownNCT04996771Phase 1/2
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04961918Phase 2
• Newly Diagnosed GlioblastomaActive, not recruitingNCT04959500Phase 2
• Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLCCompletedNCT04951063Phase 1
• MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung CancerCompletedNCT04946019Phase 2
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
• Postoperative Music for Orbital DecompressionStatus unknownNCT04933201Not applicable
• Supramaximal Rectus Recession for Strabismus in Grave's OphthalmopathyStatus unknownNCT04927468Not applicable
• PACS System in the Training of OphthalmologistsStatus unknownNCT04926870Not applicable
• The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate CancerStatus unknownNCT04926155Phase 2
• The Effect of Metformin in Patients With Newly Diagnosed mHSPCActive, not recruitingNCT04925063Phase 2
• The Efficacy of an Artificial Intelligence Platform to Adapt Visual Aids for Patients With Low Vision: a Randomised Controlled TrialStatus unknownNCT04919837Not applicable
• Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated OphthalmopathyStatus unknownNCT04919694Not applicable
• Effects of Different Physical Therapy Programs on Pulmonary Rehabilitation in Patients With Lung CancerStatus unknownNCT04914624Not applicable
• PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Phase 3
• Early Recognition and Dynamic Risk Warning System of Multiple Organ Dysfunction Syndrome Caused by SepsisStatus unknownNCT04904289
• Immune Function Monitoring and Immunotherapy in SepsisStatus unknownNCT04903405
• Using Machine Learning to Adapt Visual Aids for Patients With Low VisionStatus unknownNCT04892316
• A Platform for Multidisciplinary Medical Artificial Intelligence DevelopmentStatus unknownNCT04890847
• Analysis of Hospitalization Data From ZOCStatus unknownNCT04890496
• A Dose-response Study of Dietary Resveratrol on Lipid Metabolism DisorderCompletedNCT04886297Phase 3
• An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer PatientsStatus unknownNCT04885413Phase 2
• Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure GlaucomaActive, not recruitingNCT04878458Not applicable
• Real-time Artificial Intelligence System for Detecting Multiple Ocular Fundus Lesions by Ultra-widefield Fundus ImagingStatus unknownNCT04859634
• Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyActive, not recruitingNCT04850235Phase 1
• KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) TrialActive, not recruitingNCT04844619Phase 1
• Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04844385Phase 2
• R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II StudyStatus unknownNCT04842487Phase 2
• Effects of Diet and Exercise Interventions on Cardiometabolic Risk Markers, Executive Function, and Intestinal FloraStatus unknownNCT04834687Not applicable
• PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal CancerActive, not recruitingNCT04833387Phase 2
• Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCCompletedNCT04833257Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Phase 2
• Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814030Phase 2
• Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical CancerCompletedNCT04799639Phase 2
• The Evaluation of Consistency by Finger Stick Blood Glucose or Venous Blood Glucose of Flash Glucose Monitoring in Different Infiltration TimeStatus unknownNCT04797416Not applicable
• Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With LymphomaStatus unknownNCT04797182Phase 2
• TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical StudyStatus unknownNCT04796025Phase 2
• Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal CancerCompletedNCT04790448Phase 1/2
• Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFRStatus unknownNCT04785742Phase 2
• Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI ResistanceStatus unknownNCT04785729Phase 2
• Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal CarcinomaStatus unknownNCT04764149
• The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
• Office Based Vergence/Accommodative Therapy for the Treatment of Intermittent ExotropiaStatus unknownNCT04744779Not applicable
• DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
• Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingNCT04724239Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.Status unknownNCT04722406
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
• CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular CarcinomaStatus unknownNCT04715321
• Development of AI Model for Uveitis Progression and PrognosisStatus unknownNCT04705103
• A Prospective, Open-label, Single-arm Clinical StudyStatus unknownNCT04689087Not applicable
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialStatus unknownNCT04687163Phase 3
• Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cmStatus unknownNCT04686942
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
• Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Phase 3

← Sun Yat-sen University overview and focus areas